Skip to main content
Clinical Trials/NCT05899660
NCT05899660
Recruiting
Not Applicable

Impact of Omega-3 Polyunsaturated Fatty Acids on Emotional, Cognitive and Biological Alterations in Alcohol Use Disorder

Université Catholique de Louvain1 site in 1 country100 target enrollmentJune 19, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alcohol Use Disorder, Severe
Sponsor
Université Catholique de Louvain
Enrollment
100
Locations
1
Primary Endpoint
Change in trauma
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder. The main questions this study aims to answer are:

  • Can n-3 PUFA improve mood disorders (depression, anxiety), craving for alcohol, cognitive impairments and sociability disorders ?
  • Are the beneficial effects of n-3 PUFAs due to a modification of the gut microbiota and/or the inflammatory status?

Participants will :

  • take a supplementation of omega-3 or placebo during 3 months
  • do a brain MRI
  • be interviewed for a dietary anamnesis
  • provide blood, stool and saliva samples
  • perform psychological tests and neuropsychological tasks

Researchers will compare active comparator (omega-3) with placebo comparator (olive oil) to see if omega-3 can have a beneficial effect on AUD patients.

Detailed Description

Alcohol use disorder (AUD) is the most widespread addiction in Belgium and Europe and constitutes a major public health problem with important physical, psychological and economic consequences for the consumer and his family, friends, co-workers. For several years, the intestinal microbiota has been increasingly studied because it seems to play an indispensable role in the proper functioning of the body. Indeed, it is involved in the regulation of the immune system, metabolic reactions and the nervous system and therefore influences behaviour. The composition of the microbiota is specific to everyone and is influenced by many factors, such as diet, medication and lifestyle. In the case of AUD, numerous studies have shown that alcohol and its metabolites alter the intestinal microbiota, leading to an increase in inflammation and changes in behaviour. Nutritional intervention is an encouraging and innovative approach to alcohol addiction therapy. The main aim of this research is to see how a nutritional intervention could improve mood, cognition and social behaviour in AUD patients. The interest will therefore focus on Omega-3. These polyunsaturated fatty acids are found in the diet, mainly in fish oils, and are constituents of the body's cell membranes and perform many physiological functions. They also play an important role in the regulation of inflammation. Studies have shown that Omega-3 supplementation can reduce symptoms of depression and have beneficial effects in autism spectrum disorders, schizophrenia, bipolar disorders and neurodegenerative diseases. They have therefore been widely studied, but their role in social interactions, which is an important factor in many mental illnesses including AUD, has not yet been studied. The investigators will conduct a randomised, placebo-controlled, double-blind study, testing the impact of Omega-3 supplementation on AUD patients undergoing a detoxification program at the Saint-Luc University Hospital, Brussels, Belgium. 100 patients will be enrolled and the Omega 3/placebo supplementation will last for 3 months. The patients will be tested 3 times: T1 (2nd day of withdrawal), T2 (18th-19th day of withdrawal) and T3 (after 3 months of supplementation). The investigators hope to see a beneficial effect of omega-3 on social, emotional and cognitive deficits as well as brain functioning (fMRI). They will investigate the mechanisms involved, namely, changes in the composition of the gut microbiota, reduction of systemic inflammation, and production of bacterial metabolites with immune or neuroactive properties.

Registry
clinicaltrials.gov
Start Date
June 19, 2023
End Date
December 31, 2027
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of alcohol use disorder (≥ 4 DSM-5 criteria)
  • Patient at the hospital for a 3 week alcohol withdrawal program
  • Gender : male and female
  • Age : between 18 and 70 years old
  • Language : french
  • Alcohol consumption less than 48 jours before admission

Exclusion Criteria

  • Presence of another addiction, except for smoking and cannabis use
  • Presence of a psychiatric comorbidity (axis 1 DSM-5)
  • Current or recent use (\< 2 months) of antibiotics, probiotics, fibre supplements
  • Current or recent (\< 2 months) use of omega-3 supplements
  • Current or recent (\< 2 months) use of oral anti-coagulants drugs
  • Current or recent (\< 2 months) double anti-platelet therapy
  • Coagulation disorders
  • Current or recent (\< 1 month) use of non-steroidal anti-inflammatory drugs and glucocorticoids
  • Morbid obesity : body mass index \> 35 kg.m-2
  • Bariatric surgery

Outcomes

Primary Outcomes

Change in trauma

Time Frame: On day 19

Post-traumatic diagnostic scale (PDS-F): calculation of score is complex and described in the related publication

Change in facial emotions recognition

Time Frame: On day 19 and day 90

Facial Emotions Recognition Task (TREF)

Change in social activity

Time Frame: On day 2, day 19 and day 90

Social Activities Questionnaire (28-196)

Change in alcohol craving

Time Frame: On day 2, day 19 and day 90

Obsessive Compulsive Drinking Scale (OCDS) (score 0-40) Higher score indicates higher craving level.

Change in decision making

Time Frame: On day 19 and day 90

Fisher Task

Change in anxiety

Time Frame: On day 2, day 19 and day 90

State-Trait Anxiety Inventory (STAI) (score 20-80) Higher score indicates higher anxiety level.

Self-stigma

Time Frame: On day 19

Self-Stigma in Alcohol Dependence (SSAD) (16-80) Higher score indicates higher self-stigma level.

Change in inhibition

Time Frame: On day 2, day 19 and day 90

Stop Signal Task

Change in depression

Time Frame: On day 2, day 19 and day 90

Beck Depression Inventory (BDI) (score 0-63) Higher score indicates higher depression level.

Change in impulsivity

Time Frame: On day 19 and day 90

Urgency Premeditation Perseverance Sensation seeking impulsive behavior scale (UPPS) : score of different subscales are calculated : "ugency" (0-48), "lack of premeditation" (0-44), "lack of perseverance" (0-40), "sensation seeking) (0-48). Higher score in the different subscales indicates higher impulsivity level.

Childhood trauma

Time Frame: On day 19

Childhood Trauma Questionnaire (CTQ) (28-144) Higher score indicates higher childhood trauma level.

Change in work memory

Time Frame: On day 2, day 19 and day 90

Letter Memory Task

Change in visual perspective taking

Time Frame: On day 19 and day 90

Visual Perspective Taking Task

Change in fatigue

Time Frame: On day 2, day 19 and day 90

Multidimensional Fatigue Inventory (MFI) (score 20-140) Higher score indicates higher fatigue level.

Change in social anxiety

Time Frame: On day 19 and day 90

Liebowitz Scale of Social Anxiety (EASL) (score 0-144) Higher score indicates higher social anxiety level.

Sociability

Time Frame: On day 19

Sociogram

Emotional intelligence

Time Frame: Day 19

Trait Emotional Intelligence Questionnaire (TEI Que-75) : calculation of score is complex and described in the related publication

Secondary Outcomes

  • Change in gut microbiota composition(On day 2, day 19 and day 90)
  • Change in markers of microbial translocation(On day 2, day 19 and day 90)
  • Change in diet profile(On day 2, day 19 and day 90)
  • Change in brain functioning(On day 2, day 19 and day 90)
  • Change in inflammation(On day 2, day 19 and day 90)
  • Intestinal permeability(On day 19)
  • Change in omega-3 levels(On day 2, day 19 and day 90)

Study Sites (1)

Loading locations...

Similar Trials